Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes (Q41035391)

25 September 2017

Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes (English)

1 reference

25 September 2017

1 reference

Claudia Cavelti-Weder

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

14

Martin F Bachmann

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

12

Philippe Saudan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Katharina Timper

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Eleonora Seelig

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Cornelia Keller

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Martin Osranek

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Ute Lässing

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Gunther Spohn

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Patrik Maurer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Philipp Müller

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Gary T Jennings

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Joerg Willers

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Marc Y Donath

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

1 reference

21 December 2015

1 reference

25 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

1003-1012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes

9 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

Targeting inflammation in the treatment of type 2 diabetes: time to start

26 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes

26 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

26 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes

26 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

Cryopyrin-associated periodic syndromes: diagnosis and management

26 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

Vaccines against non-communicable diseases

26 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

A vaccine against nicotine for smoking cessation: a randomized controlled trial

26 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study

26 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

26 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity

26 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

Therapeutic vaccination for chronic diseases: a new class of drugs in sight

26 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation

26 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

IgG autoantibodies against interleukin 1 alpha in sera of normal individuals

26 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

High-avidity autoantibodies to cytokines

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

Anti-interleukin-6 antibodies in normal human serum

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4881764

Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors. II. Phase II study of the protective effect of recombinant human interleukin-1 beta on myelodepres

19 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26686385

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26686385

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors. I. Phase I-II clinical trials of recombinant human interleukin-1 beta as a leukopoiesis stimulator

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26686385

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/MT.2015.227

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26686385%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

PubMed publication ID

26686385

1 reference